Sign in Subscribe
Class action lawsuits

Altimmune Investors File Class Action Lawsuit Over Securities Fraud Allegations

Strategic Insights

— 1 min read

Altimmune investors who lost money on the stock between August 10, 2023, and June 25, 2025, may be able to recover their losses through a class action lawsuit filed against the company over alleged securities fraud. The lawsuit stems from Altimmune's announcement of topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which showed a lack of statistical significance in the fibrosis reduction primary endpoint. When questioned about the disappointing results, the company attributed it to the Phase 2 nature of the trial and stated that they were hoping for better results in the Phase 3 trial. The stock price plummeted after the announcement, falling 53.2% in just one day.

Key Takeaways:

  • The class action lawsuit seeks to recover losses for Altimmune investors who were allegedly affected by securities fraud between August 10, 2023, and June 25, 2025.
  • The lawsuit focuses on the company's announcement of topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to meet statistical significance in the fibrosis reduction primary endpoint.
  • Altimmune attributed the disappointment to the Phase 2 nature of the trial, stating that they were hoping for better results in the Phase 3 trial.
  • The stock price of Altimmune's common stock declined dramatically after the announcement, from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, a decline of 53.2% in one day.
  • Investors who suffered losses during the relevant time frame have until October 6, 2025, to request that the Court appoint them as lead plaintiff.
  • Participation in the lawsuit requires no payment of any out-of-pocket costs or fees, and there is no obligation to participate.

Statistics:

  • Decline in Altimmune's stock price: 53.2% in one day, from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025.
  • Time frame for the alleged securities fraud: August 10, 2023, to June 25, 2025.
  • Deadline for requesting lead plaintiff appointment: October 6, 2025.

Sources:

  • https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=160454&wire=3
  • Email: jlevi@levikorsinsky.com
  • Phone: (212) 363-7500
  • Fax: (212) 363-7171
  • Website: www.zlk.com

Read more